A Form 4 filed on August 19, 2026, with the U.S. Securities and Exchange Commission disclosed that Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, Inc. (NASDAQ:CADL), sold 7,000 shares of common stock on August 17, 2026, pursuant to a pre-established 10b5-1 trading plan.

Key Highlights

  • Reporting person: Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, Inc.
  • Transaction: Disposition (transaction code S) of 7,000 shares of common stock on August 17, 2026.
  • Sale price: $12 per share, as reported in the filing.
  • Remaining ownership: 76,865 shares of common stock beneficially owned directly following the transaction.
  • Trading plan: The sale was effected pursuant to a 10b5-1 trading plan adopted on March 16, 2026.

Candel Therapeutics CTO Share Sale Details and Post-Transaction Ownership

According to the filing, Seshu Tyagarajan, serving as Chief Technology Officer of Candel Therapeutics, Inc., disposed of 7,000 shares of the company's common stock on August 17, 2026, at a price of $12 per share. The transaction is recorded with code "S" in Table I of the Form 4, reflecting an open-market sale of directly held shares. No derivative securities transactions were reported.

The filing notes that the transaction was made pursuant to a Rule 10b5-1(c) trading plan, which the form indicates was adopted on March 16, 2026. The Form 4 was signed by Charles Schoch as Attorney-in-Fact for Seshu Tyagarajan and filed on August 19, 2026. Following the reported sale, Tyagarajan directly and beneficially owned 76,865 shares of Candel Therapeutics common stock, according to the filing.

No Table II derivative security transactions were reported in connection with this filing. The issuer is identified in the filing as Candel Therapeutics, Inc., traded under the ticker CADL on NASDAQ, with the company's address listed as 117 Kendrick St., Suite 450, Needham, Massachusetts 02494.

What Was Disclosed

The filing disclosed a sale of 7,000 shares of Candel Therapeutics common stock by its Chief Technology Officer at $12 per share on August 17, 2026, conducted under a 10b5-1 plan adopted March 16, 2026, leaving the officer with 76,865 directly held shares.